Table 3.
Number of patients | Tumor classification (WHO grading) | Definition of supratotal resection | Number of supratotal resection case (%) | Adjuvant therapy | Clinical outcome | Mean follow-up duration and outcomes | |
---|---|---|---|---|---|---|---|
Motomura et al. (53) | 9 | WHO grade II glioma, WHO grade III glioma | Tumor resection extending beyond the abnormal MRI-verified area, which indicated that the volume of the postoperative cavity was larger than the preoperative tumor volume | 9 (100%) | NA | WMS-R, SLTA, FAB, WAIS-III | NA NA |
Rossi et al. (70) | 319 | WHO grade II glioma, WHO grade III glioma | Complete removal of any signal abnormalities, with the volume of the postoperative cavity larger than preoperative tumor volume | 110 (35%) | Chemoradiotherapy (17.6%), chemotherapy only (41.2%) | Adjuvant treatment, anaplastic transformation, postop seizures, recurrence rate, OS, PFS, MPFS | 6.8 years PFS at 92 months; 94% |
WHO, World Health Organization; WMS-R; Wechsler memory scale revised, SLTA; Standard Language Test of Aphasia, FAB; Frontal Assessment Battery, WAIS-III; the third version of Wechsler adult intelligence score; OS, overall survival; PFS, progression free survival; MPFS, malignant progression free survival, NA, not available.